| ²é¿´: 227 | »Ø¸´: 3 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
gaoshandian1½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
mingcijieshi1
|
||
|
A Abundance (mRNA ·á¶È)£ºÖ¸Ã¿¸öϸ°ûÖÐmRNA ·Ö×ÓµÄÊýÄ¿¡£ Abundant mRNA(¸ß·á¶ÈmRNA)£ºÓÉÉÙÁ¿²»Í¬ÖÖÀàmRNA×é³É£¬Ã¿Ò»ÖÖÔÚϸ°ûÖгöÏÖ´óÁ¿¿½±´¡£ Acceptor splicing site (ÊÜÌå¼ôÇÐλµã)£ºÄÚº¬×ÓÓÒÄ©¶ËºÍÏàÁÚÍâÏÔ×Ó×óÄ©¶ËµÄ±ß½ç¡£ Acentric fragment(ÎÞ×ÅË¿Á£Æ¬¶Î)£º(ÓÉ´ò¶Ï²úÉúµÄ)ȾɫÌåÎÞ×ÅË¿Á£Æ¬¶ÎȱÉÙÖÐÐÄÁ££¬´Ó¶øÔÚϸ°û·Ö»¯Öб»¶ªÊ§¡£ Active site(»îÐÔλµã)£ºµ°°×ÖÊÉÏÒ»¸öµ×Îï½áºÏµÄÓÐÏÞÇøÓò¡£ Allele(µÈλ»ùÒò)£ºÔÚȾɫÌåÉÏÕ¼¾Ý¸ø¶¨Î»µã»ùÒòµÄ²»Í¬ÐÎʽ¡£ Allelic exclusion(µÈλ»ùÒòÅųâ)£ºÐÎÈÝÔÚÌØÊâÁܰÍϸ°ûÖÐÖ»ÓÐÒ»¸öµÈλ»ùÒòÀ´±í´ï±àÂëµÄÃâÒßÇòµ°°×ÖÊ¡£ Allosteric control(±ð¹¹µ÷¿Ø)£ºÖ¸µ°°×ÖÊÒ»¸öλµãÉϵķ´Ó¦Äܹ»Ó°ÏìÁíÒ»¸öλµã»îÐÔµÄÄÜÁ¦¡£ Alu-equivalent family(Alu Ï൱ÐòÁлùÒò)£º²¸È鶯Îï»ùÒò×éÉÏÒ»×éÐòÁУ¬ËüÃÇÓëÈËÀàAlu ¼Ò×åÏà¹Ø¡£ Alu family (Alu¼Ò×å)£ºÈËÀà»ùÒò×éÖÐһϵÁзÖÉ¢µÄÏà¹ØÐòÁУ¬Ã¿¸öÔ¼300bp³¤¡£Ã¿¸ö³ÉÔ±ÆäÁ½¶ËÓÐAlu Çиîλµã(Ãû×ÖµÄÓÉÀ´)¡£ ¦Á-Amanitin(¶ì¸àñû¼î)£ºÊÇÀ´×Ô¶¾Ä¢¹½Amanita phalloides ¶þ»·°ËëÄ£¬ÄÜÒÖÖÆÕæºËRNA¾ÛºÏø£¬ÌرðÊǾۺÏøII ת¼¡£ Amber codon (çúçêÃÜÂë×Ó)£ººËÜÕËáÈýÁªÌåUAG£¬ÒýÆðµ°°×ÖʺϳÉÖÕÖ¹µÄÈý¸öÃÜÂë×ÓÖ®Ò»¡£ Amber mutation (çúçêÍ»±ä)£ºÖ¸´ú±íµ°°×ÖÊÖа±»ùËáÃÜÂë×ÓÕ¼¾ÝµÄλµãÉÏÍ»±ä³ÉçúçêÃÜÂë×ÓµÄÈκÎDNA ¸Ä±ä¡£ Amber suppressors (çúçêÒÖÖÆ×Ó)£º±àÂëtRNAµÄ»ùÒòÍ»±äʹÆä·´ÃÜÂë×Ó±»¸Ä±ä£¬´Ó¶øÄÜʶ±ðUAG ÃÜÂë×ÓºÍ֮ǰµÄÃÜÂë×Ó¡£ Aminoacyl-tRNA (°±õ£-tRNA)£ºÊÇЯ´ø°±»ùËáµÄתÔËRNA£¬¹²¼ÛÁ¬½ÓλÔÚ°±»ùËáµÄNH2»ùÍźÍtRNA ÖÕÖ¹¼î»ùµÄ3¡é»òÕß2¡é£OH »ùÍÅÉÏ¡£ Aminoacyl-tRNA synthetases (°±õ£-tRNA ºÏ³Éø)£º´ß»¯°±»ùËáÓëtRNA 3¡é»òÕß2¡é£OH»ùÍŹ²¼ÛÁ¬½ÓµÄø¡£ Amphipathic structure(Á½Ç׽ṹ)£º¾ßÓÐÁ½¸ö±íÃæ£¬Ò»¸öÇ×Ë®£¬Ò»¸öÊèË®¡£Ö¬ÀàÊÇÁ½Ç׽ṹ£¬Ò»¸öµ°°×ÖʽṹÓòÄܹ»ÐγÉÁ½Ç×ÂÝÐý£¬ÓµÓÐÒ»´ø µçµÄ±íÃæºÍÖÐÐÔ±íÃæ¡£ Amplification (À©Ôö)£ºÖ¸²úÉúÒ»¸öȾɫÌåÐòÁжîÍ⿽±´£¬ÒÔȾɫÌåÄÚ»òÕßȾɫÌåÍâDNAÐΠʽ´Ø´æÔÚ¡£ Anchorage dependence (Ìù±ÚÒÀÀµ)£ºÖ¸Õý³£µÄÕæºËϸ°ûÐèÒªÎü¸½±íÃæ²ÅÄÜÔÚÅàÑø»ùÉÏÉú³¤¡£ Aneuploid (·ÇÕû±¶Ìå)£º×é³ÉÓëͨ³£µÄ¶à±¶Ìå½á¹¹²»Í¬£¬È¾É«Ìå»òÕßȾɫÌ寬¶Î»ò³É±¶¶ªÊ§¡£ Annealing (ÍË»ð)£ºÁ½Ìõ»¥²¹µ¥Á´Åä¶ÔÐγÉË«ÂÝÐý½á¹¹¡£ Anterograde (˳ʽתÔË)£ºµ°°×ÖÊÖÊ´ÓÄÚÖÊÍøÑØ×Ÿ߶û»ùÌåÏòÖÊĤתÔË¡£ Antibody (¿¹Ìå)£ºÓÉB ÁܰÍϸ°û²úÉúµÄµ°°×ÖÊ(ÃâÒßÇòµ°°×ÖÊ)£¬ËüÄÜʶ±ðÌØÊâµÄÍâÔ´¡°¿¹Ô¡±£¬´Ó¶øÒýÆðÃâÒßÓ¦´ð¡£ Anticoding strand (·´±àÂëÁ´)£ºDNA Ë«Á´ÖÐ×÷ΪĤ°åÖ¸µ¼ÓëÖ®»¥²¹µÄRNA ºÏ³ÉµÄÁ´¡£ Antigen (¿¹Ô)£º½øÈë»ùÌåºóÄÜÒýÆð¿¹Ìå(ÃâÒßÇòµ°°×ÖÊ)ºÏ³ÉµÄ·Ö×Ó¡£ Antiparallel (·´Ê½Æ½ÐÐ)£ºDNAË«ÂÝÐýÒÔÏà·´µÄ·½Ïò×éÖ¯£¬Òò´ËÒ»ÌõÁ´µÄ5¡é¶ËÓëÁíÒ»ÌõÁ´µÄ3¡é¶ËÏàÁ¬¡£ Antitermination protein (¿¹ÖÕÖ¹µ°°×ÖÊ)£ºÄܹ»Ê¹RNA¾ÛºÏøͨ¹ýÒ»¶¨µÄÖÕֹλµãµÄµ°°×ÖÊ ÖÊ¡£ AP endonucleases (AP ºËËáÄÚÇÐø)£º¼ôÇеôDNA 5¡é¶ËÍÑàÑßʺÍÍÑà×à¤Î»µãµÄø Apoptosis (ϸ°ûµòÍö)£ºÏ¸°û½øÐгÌÐòÐÔËÀÍöµÄÄÜÁ¦£»¶Ô´Ì¼¤Ó¦´ðʹͨ¹ýһϵÁÐÌØ¶¨·´Ó¦´Ý»Ùϸ°ûµÄ;¾¶·¢Éú¡£ Archeae (¹Åϸ¾ú)£º½ø»¯ÖÐÓëԺ˺ÍÕæºË²»Í¬µÄÒ»¸ö·ÖÖ§¡£ Ascue (×ÓÄÒ)£ºÕæ¾úµÄ×ÓÄÒ°üº¬Ëĸö»ò°Ë¸ö(µ¥Ò»µÄ)æß×Ó£¬±íʾһ´Î¼õÊý·ÖÁѵIJúÎï¡£ Att sites (Attλµã)£ºÔÚÊɾúÌåºÍϸ¾úȾɫÌåÖн«ÊɾúÌå²åÈë»òÇгýϸ¾úȾɫÌåµÄλµã¡£ Attenuation (Ë¥¼õ)£º¿ØÖÆÒ»Ð©Ï¸¾úÆô¶¯×Ó±í´ïÖÐÉæ¼°µÄת¼ÖÕÖ¹µ÷¿Ø¡£ Attenuator (Ë¥¼õ×Ó)£ºË¥¼õ·¢Éú´¦µÄÒ»ÖÖÄÚ²¿ÖÕÖ¹×ÓÐòÁС£ Autogenous control (×ÔÌåµ÷¿Ø)£º»ùÒò²úÎï¼õÈõ(¸º×ÔÌåµ÷¿Ø)»òÕß¼¤»î(Õý×ÔÌåµ÷¿Ø)Æä±àÂë»ù Òò±í´ïµÄ×÷ÓᣠAutonomous controlling element (×ÔÖ÷¿ØÖÆÔª¼þ)£ºÓñÃ×ÖÐÒ»ÖÖ¾ßÓÐת×ùÄÜÁ¦µÄת×ùÔª¼þ¡£ Autoradiography (·ÅÉäÐÔ×ÓÏÔÓ°)£ºÍ¨¹ý·ÅÉäÐÔ±ê¼Ç·Ö×ÓÔÚ½º¾íÉÏÁôÏÂͼÏñ¼ì²â·Ö×ӵķ½·¨¡£ Autosomes (³£È¾É«Ìå)£º³ýÐÔȾɫÌåÍâµÄËùÓÐȾɫÌå¡£¶þ±¶Ìåϸ°ûÓµÓÐÁ½Ì׳£È¾É«Ìå¡£ |
» ²ÂÄãϲ»¶
¹ØÓÚÖØ¸´µ÷²éºÍÖØ¸´²âÁ¿µÄÎÊÌ⣬°Ù˼²»µÃÆä½â£¡
ÒѾÓÐ1È˻ظ´
°Ä´óÀûÑÇÀ¥Ê¿À¼´óѧÕÐÊÕÉúÎï²ÄÁϺÍϸ°ûÍâÄÒÅÝ·½ÏòCSCÁªºÏÅàÑø²©Ê¿Éú
ÒѾÓÐ7È˻ظ´
Ô˶¯ÏµÍ³ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ223È˻ظ´
»¤Àí±¾£¬¹«ÎÀ˶£¬¾ÍÒµ»¹ÊÇ»¤Àí²©
ÒѾÓÐ1È˻ظ´
Éç»áҽѧÓëÎÀÉúÊÂÒµ¹ÜÀí·½Ïò¿¼²©ÓÐûÓе¼Ê¦ÊÕÁô
ÒѾÓÐ1È˻ظ´
¼ª´ó¹«ÎÀ357Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Çó¾«Í¨crisper/cas9µÄ´óÀаïÖú
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸Öдó¹«ÎÀÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Öдó¹«ÎÀ303·ÖÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
1
|
2Â¥2006-05-17 07:59:07
1
|
3Â¥2006-05-17 08:53:45
huangrong
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 8314.3
- Ìû×Ó: 396
- ÔÚÏß: 47.2Сʱ
- ³æºÅ: 166079
- ×¢²á: 2006-01-13
- ÐÔ±ð: MM
- רҵ: ºôÎüϵͳ¼²²¡ÕïÁÆÐ¼¼Êõ
4Â¥2006-05-17 12:07:52














»Ø¸´´ËÂ¥